Bach & Godofsky Infectious Diseases

Recent papers from Bach & Godofsky Infectious Diseases

1. Idx184 in Combination with Pegylated Interferon-α2A and Ribavirin for 2 Weeks in Treatment-Naive Patients with Chronic Hepatitis CAntiviral Therapy · 2013
2. Safety, Pharmacokinetics, and Antiretroviral Activity of Multiple Doses of Ibalizumab (formerly TNX-355), an Anti-CD4 Monoclonal Antibody, in Human Immunodeficiency Virus Type 1-Infected AdultsAntimicrobial Agents and Chemotherapy · 2008
3. High relapse rate seen at week 72 for patients treated with R1626 combination therapy†Hepatology · 2008
4. R1626 plus peginterferon Alfa‐2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin†Hepatology · 2008
5. Efficacy and Safety of 48 Weeks of Enfuvirtide 180 mg Once-Daily Dosing Versus 90 mg Twice-Daily Dosing in HIV-Infected PatientsHIV Clinical Trials · 2008
6. Enfuvirtide Does Not Require Dose Adjustment in Patients With Chronic Kidney FailureJAIDS Journal of Acquired Immune Deficiency Syndromes · 2008
7. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patientsHepatology · 2007
8. Antiretroviral Activity of the Anti‐CD4 Monoclonal Antibody TNX‐355 in Patients Infected with HIV Type 1The Journal of Infectious Diseases · 2004
9. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapyAIDS · 2000